EP0909171B1 - Use of l-acetylcarnitine, l-isovalerylcarnitine, l-propionylcarnitine for increasing the levels of igf-1 - Google Patents
Use of l-acetylcarnitine, l-isovalerylcarnitine, l-propionylcarnitine for increasing the levels of igf-1 Download PDFInfo
- Publication number
- EP0909171B1 EP0909171B1 EP97922035A EP97922035A EP0909171B1 EP 0909171 B1 EP0909171 B1 EP 0909171B1 EP 97922035 A EP97922035 A EP 97922035A EP 97922035 A EP97922035 A EP 97922035A EP 0909171 B1 EP0909171 B1 EP 0909171B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- igf
- acetylcarnitine
- isovalerylcarnitine
- propionylcarnitine
- pct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Revoked
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Definitions
- the present invention relates to a novel therapeutic use of L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine or pharmacologically acceptable salts thereof for increasing the levels of IGF-1 (insulin-like growth factor 1) for the therapeutic treatment or prophylaxis of cytological disorders or diseases related to IGF-1. More particularly, the present invention relates to the use of L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine or pharmacologically acceptable salts thereof for the therapeutic treatment or prophylaxis of individuals in whom IGF-1 contributes towards the pathogenesis of a particular disease or provokes cytological disorders.
- IGF-1 insulin-like growth factor 1
- IGF-1 promotes cell growth and differentiation.
- the administration of IGF-1 obtained as a protein purified by molecular biology methods has made it possible to confirm the effects observed in vitro with cells, on animal models and in man.
- the action of IGF-1 is similar to that of insulin, that is to say an increase in the uptake of glucose, a reduction in ketones and fatty acids in the serum and an increase in protein synthesis.
- clinical studies have been undertaken in order to evaluate the efficacy of IGF-1 in a range of diseases.
- IGF-1 has been administered to patients with type-II diabetes, to cachectic patients, to patients with ischemic damage at the neuronal, myocardial or renal level, and has been proposed for repairing and regenerating tissues (W.L. Lowe, Insulin-like growth factors, Scientific American Science and Medicine p. 62, March 1996).
- IGF-1 may be therapeutically useful in various morbid conditions.
- diseases or disorders which may be prevented, cured or improved by the administration of IGF-1 include neuropathies of the optic nerve and of the olfactory nerve, neuralgia of the trigeminal nerve, Bell's paralysis, arthropathy, arthritis, cervical spondylosis and hernia of the intervertebral discs, clinical syndromes of reduced height, cachexia, acute or chronic hepatic necrosis, Turner's syndrome, sarcopoenia, growth hormone insensitivity syndromes, obesity, myasthenia and heart asthenia IGF-1 moreover appears to be useful for the cicatrization of wounds, the healing of ulcers, the treatment of burns, tissue regeneration in general and in particular that of cutaneous, intestinal and hepatic tissue, and the formation of dentine.
- the administration of L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine or pharmacologically acceptable salts thereof is capable of inducing the production of IGF-1 without the undesirable effects produced by the administration of exogenous IGF-1.
- pharmacologically acceptable salt of L-acetylcarnitine, of L-isovalerylcarnitine or of L-propionylcarnitine is understood to refer to any salt of the above with an acid which does not give rise to undesirable toxicity or side-effects.
- acids are well known to pharmacologists and to experts in the pharmaceutical field.
- Non-limiting examples of such salts are: chloride; bromide; iodide; aspartate, in particular hydrogen aspartate; citrate, in particular hydrogen citrate; tartrate; phosphate, in particular hydrogen phosphate; fumarate, in particular hydrogen fumarate; glycerophosphate, glucose phosphate; lactate; maleate, in particular hydrogen maleate; orotate; oxalate, in particular hydrogen oxalate; sulphate, in particular hydrogen sulphate; trichloroacetate, trifluoroacetate and methanesulphonate.
- the present invention relates to the use of acetyl L- carnitine only.
- L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine or pharmaceutically acceptable salts thereof are capable of increasing the levels of IGF-1 in human biological fluids. It should be emphasized that, on the basis of extensive supporting scientific literature, the mechanism of action of L-acetylcarnitine has been focused at the metabolic level, more specifically demonstrating a protective action with respect to the mitochondria, whereas the present invention demonstrates an action mediated by the production of IGF-1.
- the L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine or pharmaceutically acceptable salts thereof are administered in combination with vasodilatory, vascular, endocrinological, immunological, cytostatic, immunomodulatory, anti-inflammatory or cortisone pharmaceutical products, IGF-1, IGF-1 binding proteins, growth hormones and other cell growth factors such as, for example, epidermal growth factor, and erythropoietin.
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITRM960479 | 1996-07-05 | ||
IT96RM000479A IT1290801B1 (it) | 1996-07-05 | 1996-07-05 | Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili |
PCT/IT1997/000113 WO1998001128A1 (en) | 1996-07-05 | 1997-05-15 | Use of l-acetylcarnitine, l-isovalerylcarnitine, l-propionylcarnitine for increasing the levels of igf-1 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0909171A1 EP0909171A1 (en) | 1999-04-21 |
EP0909171B1 true EP0909171B1 (en) | 2004-08-18 |
Family
ID=11404324
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97922035A Revoked EP0909171B1 (en) | 1996-07-05 | 1997-05-15 | Use of l-acetylcarnitine, l-isovalerylcarnitine, l-propionylcarnitine for increasing the levels of igf-1 |
Country Status (11)
Country | Link |
---|---|
US (2) | US6037373A (pt) |
EP (1) | EP0909171B1 (pt) |
JP (1) | JP2000514437A (pt) |
KR (1) | KR100479669B1 (pt) |
AT (1) | ATE273701T1 (pt) |
CA (1) | CA2260145C (pt) |
DE (1) | DE69730330T2 (pt) |
ES (1) | ES2225968T3 (pt) |
IT (1) | IT1290801B1 (pt) |
PT (1) | PT909171E (pt) |
WO (1) | WO1998001128A1 (pt) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1290801B1 (it) * | 1996-07-05 | 1998-12-11 | Mendes Srl | Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili |
US6380252B1 (en) * | 1996-07-05 | 2002-04-30 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine for increasing the levels of IGF-1 |
DE19718826A1 (de) * | 1997-05-05 | 1998-11-12 | Marion S Dr Eckmiller | Verwendung biologisch aktiver Wirkstoffe zum Beeinflussen des Extrazellulär-Raumes von Sinneszellen und Verfahren zur Wirkstoff-Administrationssteuerung |
IT1306178B1 (it) | 1999-07-27 | 2001-05-30 | Sigma Tau Ind Farmaceuti | Uso della l-carnitina e dei suoi alcanoil derivati per la preparazionedi un medicamento utile nel trattamento del paziente affetto da |
IT1316990B1 (it) * | 2000-02-17 | 2003-05-26 | Sigma Tau Ind Farmaceuti | Metodo per aumentare l'espressione genica per geni trasfettati. |
US20010025027A1 (en) * | 2000-03-07 | 2001-09-27 | Sonis Stephen T. | Inhibition of ceramide for the prevention and treatment of oral mucositis induced by antineoplastic drugs or radiation |
IT1317937B1 (it) * | 2000-11-17 | 2003-07-15 | Sigma Tau Healthscience Spa | Composizione per stimolare le difese immunitarie ed il metabolismo delferro comprendente una alcanoil l-carnitina e lattoferrina. |
IT1317938B1 (it) * | 2000-11-17 | 2003-07-15 | Sigma Tau Healthscience Spa | Composizione per la prevenzione e/o il trattamento di alterazioni delmetabolismo lipidico, delle forme allergiche e per attivare le difese |
IT1317079B1 (it) | 2000-12-21 | 2003-05-26 | Sigma Tau Ind Farmaceuti | Uso della isovaleril l-carnitina per la preparazione di un medicamentoper la prevenzione e cura dell'osteoporosi. |
ITRM20010708A1 (it) | 2001-12-04 | 2003-06-04 | Sigma Tau Ind Farmaceuti | Uso di una alcanoil l-carnitina per il trattamento della disfunzione erettile. |
US6652891B2 (en) | 2001-12-12 | 2003-11-25 | Herbasway Laboratories, Llc | Co-enzyme Q10 dietary supplement |
CA2369810C (en) * | 2002-01-30 | 2007-08-07 | 1474791 Ontario Limited | Method of treating pain |
US20050106183A1 (en) * | 2002-01-31 | 2005-05-19 | Lamb Gregory B. | Method of treating pain |
US7700074B2 (en) * | 2002-02-07 | 2010-04-20 | Pettegrew Jay W | Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism |
US7407778B2 (en) | 2002-02-07 | 2008-08-05 | Pettegrew Jay W | Compounds, compositions and methods for treating neuropsychiatric disorders |
US7026312B2 (en) | 2002-03-14 | 2006-04-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof |
ITRM20020492A1 (it) * | 2002-10-01 | 2004-04-02 | Sigma Tau Ind Farmaceuti | Uso della propionil l-carnitina per la preparazione di un medicamento per il trattamento del glaucoma. |
ITRM20020620A1 (it) | 2002-12-13 | 2004-06-14 | Sigma Tau Ind Farmaceuti | Uso delle carnitine per la prevenzione e/o il trattamento dei disturbi causati dall'andropausa. |
US7776913B2 (en) * | 2002-12-13 | 2010-08-17 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Carnitines for treating or preventing disorders caused by andropause |
CN1795198B (zh) * | 2003-05-29 | 2011-08-17 | 杰伊·W·佩特格尤 | 对神经精神疾病进行医学成像所用的甘油磷酸胆碱及其衍生物 |
US20060257842A1 (en) * | 2003-05-29 | 2006-11-16 | Pettegrew Jay W | Cryopreservation media and molecules |
US8173618B2 (en) * | 2003-07-25 | 2012-05-08 | University Of Massachusetts | Formulations for reducing neuronal degeneration |
US20050232911A1 (en) * | 2004-04-19 | 2005-10-20 | Schreiber Brian D | Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid |
EP1871883A1 (en) | 2005-03-02 | 2008-01-02 | Metanomics GmbH | Process for the production of fine chemicals |
JP2006347935A (ja) * | 2005-06-15 | 2006-12-28 | Masanori Ogata | 炎症性サイトカインの産生が関与する疾患の予防及び/又は治療のための医薬 |
US20070087975A1 (en) * | 2005-10-17 | 2007-04-19 | Sigma-Tau Industrie Farmaceutiche Riunite Spa | Compound useful for the prevention and treatment of left ventricular hypertrophy in dialysed patients |
KR100738959B1 (ko) | 2006-02-09 | 2007-07-12 | 주식회사 하이닉스반도체 | 반도체 메모리 장치의 센스 앰프 전원 공급 회로 및 방법 |
US7957213B2 (en) * | 2006-02-09 | 2011-06-07 | Hynix Semiconductor, Inc. | Semiconductor memory apparatus |
WO2008036682A2 (en) | 2006-09-18 | 2008-03-27 | Raptor Pharmaceutical Inc. | Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates |
JP5982091B2 (ja) * | 2007-03-21 | 2016-08-31 | シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニSigma−Tau Industrie Farmaceutiche Riunite Societa Per Azioni | インスリン耐性を有する前糖尿病患者における2型糖尿病およびその合併症の予防に有用な組成物 |
WO2008134828A2 (en) | 2007-05-04 | 2008-11-13 | Katholieke Universiteit Leuven | Tissue degeneration protection |
KR20100017460A (ko) * | 2007-05-24 | 2010-02-16 | 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. | 피피에이알 감마 작용물질로 인한 부작용의 예방에 유용한 조성물 |
US8597640B2 (en) * | 2007-10-31 | 2013-12-03 | University Of Massachusetts Lowell | Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging |
US20120077778A1 (en) | 2010-09-29 | 2012-03-29 | Andrea Bourdelais | Ladder-Frame Polyether Conjugates |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1245699B (it) * | 1991-05-29 | 1994-10-14 | Sigma Tau Ind Farmaceuti | Derivati della l-carnitina quali agenti terapeutici per il trattamento delle miopatie, della degenarazione neuronale e per inibire la proteolisi |
US5240961A (en) * | 1992-07-02 | 1993-08-31 | Shug Austin L | Method of treating reduced insulin-like growth factor and bone loss associated with aging |
WO1995000137A1 (de) * | 1993-06-21 | 1995-01-05 | Bernardini, Attilio | Verwendung von acylcarnitin zur behandlund von aids-krankheiten |
IT1290801B1 (it) * | 1996-07-05 | 1998-12-11 | Mendes Srl | Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili |
-
1996
- 1996-07-05 IT IT96RM000479A patent/IT1290801B1/it active IP Right Grant
-
1997
- 1997-05-15 ES ES97922035T patent/ES2225968T3/es not_active Expired - Lifetime
- 1997-05-15 WO PCT/IT1997/000113 patent/WO1998001128A1/en active IP Right Grant
- 1997-05-15 AT AT97922035T patent/ATE273701T1/de active
- 1997-05-15 DE DE69730330T patent/DE69730330T2/de not_active Expired - Lifetime
- 1997-05-15 KR KR10-1998-0710960A patent/KR100479669B1/ko not_active IP Right Cessation
- 1997-05-15 EP EP97922035A patent/EP0909171B1/en not_active Revoked
- 1997-05-15 CA CA002260145A patent/CA2260145C/en not_active Expired - Fee Related
- 1997-05-15 JP JP10505011A patent/JP2000514437A/ja active Pending
- 1997-05-15 PT PT97922035T patent/PT909171E/pt unknown
- 1997-05-15 US US09/147,465 patent/US6037373A/en not_active Expired - Fee Related
-
2000
- 2000-02-22 US US09/510,672 patent/US6166077A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ATE273701T1 (de) | 2004-09-15 |
EP0909171A1 (en) | 1999-04-21 |
ITRM960479A0 (pt) | 1996-07-05 |
ITRM960479A1 (it) | 1998-01-05 |
WO1998001128A1 (en) | 1998-01-15 |
DE69730330D1 (de) | 2004-09-23 |
DE69730330T2 (de) | 2005-02-10 |
IT1290801B1 (it) | 1998-12-11 |
JP2000514437A (ja) | 2000-10-31 |
PT909171E (pt) | 2004-11-30 |
US6037373A (en) | 2000-03-14 |
CA2260145A1 (en) | 1998-01-15 |
KR100479669B1 (ko) | 2005-06-13 |
CA2260145C (en) | 2007-01-09 |
KR20000022515A (ko) | 2000-04-25 |
US6166077A (en) | 2000-12-26 |
ES2225968T3 (es) | 2005-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0909171B1 (en) | Use of l-acetylcarnitine, l-isovalerylcarnitine, l-propionylcarnitine for increasing the levels of igf-1 | |
JP5086322B2 (ja) | Mcp−1プロテインの増加生産によって特徴付けられる障害の処置のための薬剤組成物 | |
US20040242491A1 (en) | Composition containing dipeptide of histidine and alanine for reducing uric acid and method for reducing uric acid using the dipeptide | |
JPH085786B2 (ja) | 末梢神経障害の治療処置におけるアセチル−l−カルニチンの使用 | |
WO2014019268A1 (zh) | 一种促进神经损伤修复的药物组合物及其应用 | |
US6037372A (en) | Use of an alkanoyl-L-carnitine for the treatment of glutamate mediated diseases | |
US6380252B1 (en) | Use of L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine for increasing the levels of IGF-1 | |
BG64167B1 (bg) | Използване на заместени аминометил-хромани за профилактика на невронална дегенерация и за стимулиране на невронална регенерация | |
US9504730B2 (en) | Method of achieving a thymosin beta 4 concentration in a human patient | |
EP0376899A2 (en) | Use of L-carnitine derivatives for the manufacture of a medicament for the therapeutical treatment of peripheral neuropathies | |
KR20070008519A (ko) | 패혈증 및 유착 형성의 치료 및 예방용 조직 보호성사이토카인 | |
JPH01151514A (ja) | 神経疾患治療・予防剤 | |
RU2564907C1 (ru) | Способ лечения больных красным плоским лишаем | |
EP1248638B1 (fr) | Utilisation de l'enoxaparine pour le traitement de l'ischemie cerebrale | |
EP1937245A1 (en) | Compound useful for the prevention and treatment of left ventricular hypertrophy in dialysed patients | |
EP3207939A2 (en) | Use of a protein/peptide complex for treating and preventing atherosclerosis, method for treating and preventing atherosclerosis (variants) | |
JPWO2004035053A1 (ja) | 神経栄養因子産生促進剤 | |
JPH0840902A (ja) | 末梢神経障害および中枢神経変性疾患の治療に有用な医薬組成物 | |
RU2006140277A (ru) | Незаменимые жирные кислоты, предназначенные для предупреждения и/или лечения депрессии у пациентов, страдающих коронарной болезнью коронарной артерии | |
SU1722504A1 (ru) | Способ лечени атеросклероза коронарных сосудов | |
JPH0429936A (ja) | 悪性脳腫瘍治療用医薬組成物 | |
JPS58501949A (ja) | 患者の血清中の低密度リポタンパク質レベルを低減させる方法 | |
RU1782596C (ru) | Способ профилактики ДВС-синдрома в послеоперационном периоде | |
CN116549602A (zh) | Awrk6多肽在制备治疗银屑病药物中的用途 | |
SWAIM | PROGRESS IN ORTHOPEDIC SURGERY FOR 1943 A REVIEW PREPARED BY AN EDITORIAL BOARD OF THE AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS: XIV. CHRONIC ARTHRITIS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19990113 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. Owner name: MENDES S.R.L. |
|
17Q | First examination report despatched |
Effective date: 20010502 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: ISLER & PEDRAZZINI AG Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 69730330 Country of ref document: DE Date of ref document: 20040923 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20040403330 Country of ref document: GR |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20040917 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2225968 Country of ref document: ES Kind code of ref document: T3 |
|
ET | Fr: translation filed | ||
PLAQ | Examination of admissibility of opposition: information related to despatch of communication + time limit deleted |
Free format text: ORIGINAL CODE: EPIDOSDOPE2 |
|
PLBQ | Unpublished change to opponent data |
Free format text: ORIGINAL CODE: EPIDOS OPPO |
|
PLBI | Opposition filed |
Free format text: ORIGINAL CODE: 0009260 |
|
PLAQ | Examination of admissibility of opposition: information related to despatch of communication + time limit deleted |
Free format text: ORIGINAL CODE: EPIDOSDOPE2 |
|
PLAR | Examination of admissibility of opposition: information related to receipt of reply deleted |
Free format text: ORIGINAL CODE: EPIDOSDOPE4 |
|
PLBQ | Unpublished change to opponent data |
Free format text: ORIGINAL CODE: EPIDOS OPPO |
|
PLAB | Opposition data, opponent's data or that of the opponent's representative modified |
Free format text: ORIGINAL CODE: 0009299OPPO |
|
PLAX | Notice of opposition and request to file observation + time limit sent |
Free format text: ORIGINAL CODE: EPIDOSNOBS2 |
|
26 | Opposition filed |
Opponent name: LONZA AG Effective date: 20050518 |
|
R26 | Opposition filed (corrected) |
Opponent name: LONZA AG Effective date: 20050518 |
|
NLR1 | Nl: opposition has been filed with the epo |
Opponent name: LONZA AG |
|
PLAF | Information modified related to communication of a notice of opposition and request to file observations + time limit |
Free format text: ORIGINAL CODE: EPIDOSCOBS2 |
|
PLBB | Reply of patent proprietor to notice(s) of opposition received |
Free format text: ORIGINAL CODE: EPIDOSNOBS3 |
|
RIN2 | Information on inventor provided after grant (corrected) |
Inventor name: DE SIMONE, CLAUDIO |
|
PLAB | Opposition data, opponent's data or that of the opponent's representative modified |
Free format text: ORIGINAL CODE: 0009299OPPO |
|
R26 | Opposition filed (corrected) |
Opponent name: LONZA AG Effective date: 20050518 |
|
NLR1 | Nl: opposition has been filed with the epo |
Opponent name: LONZA AG |
|
APBP | Date of receipt of notice of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA2O |
|
APAH | Appeal reference modified |
Free format text: ORIGINAL CODE: EPIDOSCREFNO |
|
APBQ | Date of receipt of statement of grounds of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA3O |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PCAR Free format text: ISLER & PEDRAZZINI AG;POSTFACH 1772;8027 ZUERICH (CH) |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PT Payment date: 20100423 Year of fee payment: 14 Ref country code: MC Payment date: 20100420 Year of fee payment: 14 Ref country code: LU Payment date: 20100602 Year of fee payment: 14 Ref country code: IE Payment date: 20100525 Year of fee payment: 14 Ref country code: FR Payment date: 20100601 Year of fee payment: 14 Ref country code: FI Payment date: 20100527 Year of fee payment: 14 Ref country code: ES Payment date: 20100526 Year of fee payment: 14 Ref country code: DK Payment date: 20100527 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20100524 Year of fee payment: 14 Ref country code: IT Payment date: 20100526 Year of fee payment: 14 Ref country code: DE Payment date: 20100527 Year of fee payment: 14 Ref country code: AT Payment date: 20100421 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20100525 Year of fee payment: 14 Ref country code: BE Payment date: 20100525 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20100527 Year of fee payment: 14 Ref country code: GB Payment date: 20100525 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20100528 Year of fee payment: 14 |
|
APBU | Appeal procedure closed |
Free format text: ORIGINAL CODE: EPIDOSNNOA9O |
|
RDAF | Communication despatched that patent is revoked |
Free format text: ORIGINAL CODE: EPIDOSNREV1 |
|
RDAG | Patent revoked |
Free format text: ORIGINAL CODE: 0009271 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: PATENT REVOKED |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
27W | Patent revoked |
Effective date: 20110125 |
|
GBPR | Gb: patent revoked under art. 102 of the ep convention designating the uk as contracting state |
Effective date: 20110125 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: MP4A Effective date: 20110919 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R107 Ref document number: 69730330 Country of ref document: DE Effective date: 20111027 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF THE APPLICANT RENOUNCES Effective date: 20040818 Ref country code: LI Free format text: LAPSE BECAUSE OF THE APPLICANT RENOUNCES Effective date: 20040818 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: ECNC |